ArticleOncotarget2015
miR-454 functions as an oncogene by inhibiting CHD5 in hepatocellular carcinoma.
Article in Oncotarget, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 34 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
34 citing papers in PubMed, 55 citations in OpenAlex.
- miR-184 in hepatocellular carcinoma: a promising therapeutic target.Journal of physiology and biochemistry · 2025Review
- The regulation of LRPs by miRNAs in cancer: influencing cancer characteristics and responses to treatment.Cancer cell international · 2025Review
- The MicroRNA miR-454 and the mediator complex component MED12 are regulators of the androgen receptor pathway in prostate cancer.Scientific reports · 2025Article
- Predicting miRNA-disease associations using improved random walk with restart and integrating multiple similarities.Scientific reports · 2021Article
- TSPAN1 promotes autophagy flux and mediates cooperation between WNT-CTNNB1 signaling and autophagy via theAutophagy · 2021Article
- Bioinformatics analysis of mRNA and miRNA microarray to identify the key miRNA-mRNA pairs in cisplatin-resistant ovarian cancer.BMC cancer · 2021Article
- miR-101-3p Serves as a Tumor Suppressor for Renal Cell Carcinoma and Inhibits Its Invasion and Metastasis by Targeting EZH2.BioMed research international · 2021Article
- miR-454 promotes survival and induces oxaliplatin resistance in gastric carcinoma cells by targeting CYLD.Experimental and therapeutic medicine · 2020Article
- MACC1-AS1 promotes hepatocellular carcinoma cell invasion and proliferation by regulating PAX8.Aging · 2020Article
- Silencing miR-454 suppresses cell proliferation, migration and invasion via directly targeting MECP2 in renal cell carcinoma.American journal of translational research · 2020Article
- miR-454 suppresses the proliferation and invasion of ovarian cancer by targeting E2F6.Cancer cell international · 2020Article
- Neurofibromatosis type I-associated malignant peripheral nerve sheath tumors: a case report and literature review.Archives of medical science : AMS · 2020Article
- LncRNA XIST interacts with miR-454 to inhibit cells proliferation, epithelial mesenchymal transition and induces apoptosis in triple-negative breast cancer.Journal of biosciences · 2020Article
- microRNAs: Key players in virus-associated hepatocellular carcinoma.Journal of cellular physiology · 2019Review
- Pioglitazone alleviates oxygen and glucose deprivation-induced injury by up-regulation of miR-454 in H9c2 cells.Iranian journal of basic medical sciences · 2018Article
- LncRNA HOXA11-AS promotes hepatocellular carcinoma progression by repressing miR-214-3p.Journal of cellular and molecular medicine · 2018Article
- A rare CHD5 haplotype and its interactions with environmental factors predicting hepatocellular carcinoma risk.BMC cancer · 2018Article
- MicroRNA-454-3p inhibits cervical cancer cell invasion and migration by targeting c-Met.Experimental and therapeutic medicine · 2018Article
- The Role of MicroRNAs in Hepatocellular Carcinoma.Journal of Cancer · 2018Review
- Histone deacetylase 3 is associated with gastric cancer cell growth via the miR-454-mediated targeting of CHD5.International journal of molecular medicine · 2018Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors at 3 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Previous studies showed that miR-454 acted as an oncogene or tumor suppressor in cancer. However, its function in HCC remains unknown. In this study, we found that miR-454 expression was upregulated in HCC cell lines and tissues. Knockdown of miR-454 inhibited HCC cell proliferation and invasion and epithelial mesenchymal transition (EMT), whereas overexpression of miR-454 promoted HCC cell proliferation and invasion and EMT. Furthermore, we identified the CHD5 as a direct target of miR-454. CHD5 was downregulated in HCC tissues and cell lines and the expression level of CHD5 was inversely correlated with the expression of miR-454 in HCC tissues. In addition, knockdown of miR-454 inhibited the growth of HepG2-engrafted tumors in vivo. Taken together, these results indicated that miR-454 functioned as an oncogene in HCC.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.